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ABSTRACT
Objective: The objective is described to develop and validate a simple, reliable, precise, and specific analytical method for rapid separation and 
determination of N-oxide impurity in rizatriptan Benzoate active pharmaceutical ingredient bulk drug substances by reverse phase liquid 
chromatography as per the International Conference on Harmonization (ICH) guidelines.
Methods: The methodology utilized as reverse phase liquid chromatography with gradient composition. The mobile phase proportion was 
compromised mobile A containing 0.25 mm potassium dihydrogen phosphate buffer pH 2.0 and methanol (95:5 v/v) and mobile B containing 
Acetonitrile. ODS 3V, 250 × 4.6 mm, 5 µm. column. The flow rate is 1.0 ml/minute using an LC system detector at wavelength 280 nm, and the column 
oven temperature is 40°C. The chromatographic separation performed in reverse phase by the gradient composer over run time was 35 minute. The 
resolution between N-oxide and rizatriptan was recorded on the chromatogram was more than six. The developed analytical method was validated 
according to the ICH guidelines.
Results: Linearity was found in rizatriptan N-oxide over the concentration range of 450-11000 ng/ml, with the linear regression (Correlation 
coefficient R = 0.999) and proved to be robust. Limit of detection and limit of quantification of the rizatriptan N-oxide was found 150 and 450 ng/ml. 
The retention time of rizatriptan and rizatriptan N-oxide was recorded 22.6 and 24.7 minutes, respectively. The percentage recovery of N-oxide has 
been ranged from 96.0 to 102.0 in the bulk drug material sample. The proposed analytical method has been found suitable, precise, reliable, and 
accurate for the separation and quantitative determination.
Conclusion: A specific, simple, accurate, reliable, and rapid reproducible analytical method has been developed and validated for reverse phase high-
performance liquid chromatography to determine N-Oxide impurity in rizatriptan benzoate from bulk drugs material as per ICH guideline.
Keywords: Rizatriptan benzoate, N-oxide impurity, High performance liquid chromatography, Reverse phase, ODS column and validation.
The method validated at different parameters, i.e., specificity and 
system suitability, precision, limit of detection, limit of quantitation, 
robustness, linearity and range and also mobile phase stability.
INTRODUCTION
Rizatriptan benzoate, (N, N-dimethyl-2-[5-(1, 2, 4-triazole-1-ylmethyl)-
1H-indol-3-yl]ethanamine monobenzoate). Rizatriptan belongs to the 
class of triptans [1]. Rizatriptan benzoate is used to relieve the pain, 
headache, and treat to migraines [2]. It helps to return normal routine 
promptly and decreases of other pain medications [3]. Its molecular 
formula is C22H25N5O2 and molecular weight is 391.5 g/mole. Rizatriptan 
benzoate is active pharmaceutical ingredients used in manufacturing of 
finished dosage form of tablets for oral use. The chemical structures 
show rizatriptan benzoate in Fig. 1. The molecular formula of rizatriptan 
N-oxide impurity is C15H19N5O and molecular weight is 285.35 g/mole 
and chemical structures show of Fig. 2.
“Rizatriptan degradation product” refers to a compound resulting from 
a chemical modification of rizatriptan. The modification, for example, 
can be the result of a thermally or photochemically induced reaction. 
Such reactions include, without limitation, oxidation (e.g., N-oxide 
formation), elimination (e.g., E1 and E2 reaction pathways), and 
dimerization [4]. The more content of n-oxide affected to the patient 
more common is blurred vision, unusual tiredness or weakness, 
etc. Hence, it can be required to control at before commencing of 
manufacturing of finished dosage form.
The number of methods was reported to the determination of impurities 
on reverse phase high-performance liquid chromatography (HPLC), but 
there were no methods available for determination of N-oxide content 
in rizatriptan benzoate. This report describes a gradient program, 
reverse phase liquid chromatography method for the precise and rapid. 
The method was validated for quantitative determination of N-oxide in 
rizatriptan benzoate in bulk drug substances. Referred other products 
analytical method for support of method validation [5-8].
MATERIALS AND METHODS
Material and standards
Rizatriptan benzoate, N-oxide impurity kindly gifted by Lavender 
Laboratories Private Limited, Kurkumbh, Pune, Maharashtra, India.
Chemicals and reagents
Potassium dihydrogen phosphate A.R. grade, which was purchased 
from Rankem, Orthophosphoric acid A.R. grade, purchased from Mark.
Methanol used as gradient grade purchased from Thermo Fisher 
Scientific India Pvt. Ltd. Acetonitrile used as gradient grade purchased 
from Thermo Fisher Scientific India Pvt. Ltd. Purified water, HPLC and 
spectroscopy grade purchased from Finar limited.
Instrument specification
A HPLC system consists of Shimadzu 2010 series with UV detector 
and inbuilt autoinjector was utilized for method development and 
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validation. The chromatography analysis was performed using ODS 3V, 
250 × 4.6 mm internal diameter and 5 µm particle size of the column. 
The used software was LC solution software for data acquisition and 
system suitability calculation. Calibrated analytical Corporation, Japan. 
Labindia pH meter was used for pH adjustment for buffer preparation 
of mobile phase. Analytical balance used for weighing of standard and 
samples, electronic balance type 2000 Shimadzu.
Chromatographic conditions
Buffer: 0.25 mm potassium dihydrogen phosphate buffer adjusted 















Mobile phase A 
(v/v%)







The data were analyzed in the LC solution software. Before analysis, 
Mobile Phase A and Mobile Phase B was filtered through a 0.2 mm 
membrane filter and digassed to remove dissolved gases if any.
METHOD DEVELOPMENT
Rizatriptan benzoate standard solution
Accurately weighed and transferred 50 mg of rizatriptan Benzoate 
working standard into 10 ml cleaned and dried volumetric flask, added 
7 ml diluent, sonicated to dissolve and made up to the final volume with 
diluent to prepare a 5000 µg/ml solution (Stock solution A).
Rizatriptan N-oxide impurity solution
Accurately weighed and transferred 3.75 mg of rizatriptan N-oxide impurity 
standard into 50 ml cleaned and dried volumetric flask, added 35 ml 
diluent and dissolved, mixed and made up to the final volume with diluent 
to prepare a 75 µg/ml solution (Stock solution B). Further transferred 5 ml 
of this solution into 50 volumetric flask, added 35 ml diluent, mixed and 
made up to the final volume with diluent to prepare 7.5 µg/ml impurity 
standard solution w.r.t. Rizatriptan Benzoate standard solution.
Resolution solution
Transferred 1 ml of stock solution A and 1 ml of stock solution B into 
10 ml cleaned and dried volumetric flask, added 7 ml diluent, mixed and 
made up to the final volume with diluent.
VALIDATION OF DEVELOPED METHOD
Selectivity and specificity
The ability of a method to well separate and accurately measure 
specifically of selectively the eluted peaks in the presence of 
components that may be expected to be present in the sample. The 
blank, i.e., diluent, impurity, standard, resolution, solution, and test 
preparations were analyzed as per the method to identify interference 
of blank and degradation with rizatriptan N-oxide and rizatriptan 
peaks. No interference observed corresponding to the analyte peak of a 
sample solution (Figs. 3-5).
Specificity and system suitability
System suitability tests are an integral part of HPLC methods and are used 
to verify that the accuracy and precision of the system are appropriate 
for the analysis to be performed. Parameters such as tailing factor, 
resolution, and repeatability, i.e., percentage relative standard deviation 
(RSD) of retention time and area for six repetitions are determined. The 
parameters to be measured and their recommended limits obtained from 
the system suitability sample from the analysis are presented in Table 1.
Method reproducibility
Developed method was determined by has been reproduced and 
measuring repeatability by instrument precision and method precision. 
The intermediate precision was performed on different days for 
retention times and peak areas of rizatriptan N-oxide.
The instrument precision determined on six replicate injections of 
rizatriptan N-oxide. Method repeatability determined on six sample 
injections of a 7.5 µg/ml concentration solution containing 0.15% with 
respect to the concentration of sample solution. Intermediate precision 
was also determined on over a period of the day by carrying successive 
six replicate injections per day.
Fig. 1: Chemical structure: Rizatriptan benzoate
Fig. 2: N,N-dimethyl-5-(1 H-1 ,2,4-triazol-1-yl-methyl)-1 
H-indole-3- ethanamine N-oxide
Table 1: Validation results of the developed normal phase 
method
S.N Validation parameter Results
A Repeatability (n=6, %RSD)
1 Retention time of rizatriptan 0.6
2 Retention time of rizatriptan N-oxide 0.5
3 Peak area of rizatriptan 1.9
4 Peak area of rizatriptan N-oxide impurity 1.8
B Intermediate precision (n=18, %RSD)
1 Retention time of rizatriptan 0.6
2 Retention time of rizatriptan N-oxide 0.5
3 Peak area of rizatriptan 1.7
4 Peak area of rizatriptan N-oxide 1.6
C LOD-LOQ (rizatriptan N-oxide impurity)
1 Limit of detection (ng/ml) 150
2 Limit of quantification (ng/ml) 450
3 Precision at LOQ (% RSD) 1.9
D Linearity (rizatriptan N-oxide impurity)
1 Calibration range (ng/ml) 450-11000
2 Calibration points 6
3 Correlation coefficient 0.999
LOD: Limit of detection, LOQ: Limit of quantification
374
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 372-376
 Lawande 
range from the same stock solution. The RSD in percentage of the slope 
and Y-intercept of the calibration curve was calculated.
Accuracy/recovery
The sample of rizatriptan benzoate was gifted by Lavender 
Laboratories Private Limited showed the presence of N-oxide 
impurity is not detected. Recovery experiments and standard addition 
were conducted to determine the accuracy of this method for the 
quantification of rizatriptan N-oxide impurity in rizatriptan benzoate 
bulk drug samples.
The study was carried out in triplicate at 0.05%, 0.15%, and 0.25% of 
targeted analyte concentration of rizatriptan benzoate. The calculated 
recovery of the rizatriptan N-oxide was obtained by calibration curve 
from the slope and Y-intercept.
Robustness
The method robustness of an ability of the method to remain unaffected 
by small changes in method parameters, i.e., column oven temperature, 
flow rate, composition of the mobile phase. To determine the method 
robustness by experimental conditions was purposely altered 
and checked chromatographic resolution between rizatriptan and 
rizatriptan N-oxide impurity were evaluated.
The flow rate of the mobile phase was 1.0 ml/minutes. To study the 
impact of flow rate on the resolution of rizatriptan and rizatriptan 
N-oxide impurity, it was changed from 0.8 ml/minute to 1.2 ml/minute 
by 0.2 ml/minute. The effect of column oven temperature on resolution 
was changed at 38°C and 42°C instead of 40°C. While the mobile phase 
components and flow rate were held constant as stated. The effect of 
change in pH of buffer solution on resolution was studied by varying 
from	−0.1	 to	 +0.1	 and	 other	 components	 of	mobile	 phase	were	 held	
constant as stated.
Fig. 3: Typical chromatogram of blank solution
Fig. 4: Typical chromatogram of Id solution of rizatriptan N-oxide
Limit of detection (LOD) and limit of quantification (LOQ) of 
rizatriptan N-oxide
The LOD, defined as the lowest concentration of analyte that can be 
accepted at the detection level on above the baseline signal and not 
required to quantify, the signal was estimated above the baseline as 
three times the signal to noise ratio.
LOD	=	3.3	σ/S
The LOQ, defined as the lowest concentration of analyte that can be 
quantified, reproducible with suitable precision and accuracy, the 
signal was estimated as ten times the signal to noise ratio.
LOQ	=	10	σ/S
The LOD and LOQ was achieved by injecting a series of dilute solutions 
of rizatriptan N-oxide.
The developed method was precise, reliable for determination of 
rizatriptan N-oxide impurity at the LOQ level was checked by testing 
with six test solutions of rizatriptan benzoate which was prepared at 
the LOQ level and percentage RSD calculated for area response.
Linearity and range of R-isomer
Linearity of detector response was assessed by on six calibration of 
sample solutions preparation of rizatriptan N-oxide covering range 
from 450 ng/ml (LOQ) to 11000 ng/ml (450 ng/ml, 3750 ng/ml, 
5500 ng/ml, 7500 ng/ml, 9000 ng/ml, and 11000 ng/ml), solution was 
prepared in diluent.
The obtained regression curve was by plotting peak area response 
against concentration of a solution using the least squares method. 
Linearity was performed on 3 consecutive days of same concentration 
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Mobile phase stability
The stability of the mobile phase was carried out by evaluating the 
content of rizatriptan N-oxide impurity in sample solutions. Freshly 
prepared samples were injected at every 6 hrs time interval for 48 hrs. 




The aim of the work is a separation and determination of rizatriptan 
N-oxide impurity from rizatriptan benzoate using reverse phase HPLC. 
The 0.0075 mg/ml solution concentration of prepared of rizatriptan 
benzoate N-oxide impurity in diluent. Which was used while method 
development. To develop a rugged, precise, accurate, and suitable 
LC method for the separation of rizatriptan N-oxide impurity from 
rizatriptan benzoate. The different mobile phases and stationary phases 
were employed while performing the experiment. In an experiment 
has been attempted to separate the rizatriptan N-oxide impurity 
from rizatriptan benzoate. Various experiments were conducted, to 
select the best stationary and mobile phases that would give suitable 
resolution and selectivity for the separation of N-oxide impurity. 
There is an indication of separation on ODS column using a gradient 
mode for mobile phase A and mobile phase B containing composition 
of buffer: Methanol (95: 5 v/v) and acetonitrile, respectively. The 
chromatographic system equipped with detector wavelength 280 nm 
and separation was achieved on a ODS, 3V, (250 × 4.6 mm, 5 micron) 
column.
The flow rate of the mobile phase was 1.0 ml/minute. At 40°C column 
temperature, the peak shape of rizatriptan N-oxide impurity was found 
symmetrical.
In the developed and validated optimized method, the typical retention 
times of rizatriptan benzoate and rizatriptan N-oxide impurity were 
Fig. 5: Typical chromatogram of Id solution of rizatriptan
Fig. 6: Typical chromatogram of resolution solution of rizatriptan and N-oxide
about 21.7 and 24.5 minutes, respectively. The chromatographic 
separation of rizatriptan N-oxide in rizatriptan benzoate is shown 
in Fig. 6. The system suitability test results are tabulated as below 
presented in Table 2.
Validation results of the method
The percentage %RSD of rizatriptan N-oxide impurity was better 
than 0.5% for the retention time and 0.5% of the peak area response. 
However, rizatriptan was better than 0.6% for the retention time and 
0.6% of peak area response presented in Table 1. In the intermediate 
precision study, results show that values of %RSD were in the same 
manner obtained for repeatability and presented in Table 1.
The LOD and LOQ concentrations were determined 450 and 
11000 ng/ml for rizatriptan N-oxide impurity in rizatriptan benzoate 
when a signal to noise ratio of 3 for detection and 10 for quantitation 
were used as the criteria. The method precision for rizatriptan N-oxide 
impurity at the LOQ was <3% RSD presented in Table 1.
Good	linearity	was	observed	for	rizatriptan	N-oxide	impurity	over	the	
concentration range of 450-11000 ng/ml. Linearity was checked for 
rizatriptan N-oxide impurity over the same concentration range for 3 
consecutive days. The percentage RSD of the calibration curve of the 
slope and Y-intercept were 1.9 presented in Table 1.
The recovery experiments and standard addition were conducted for 
rizatriptan N-oxide impurity in bulk samples in triplicate at 0.05%, 0.15%, 
and 0.25% of analyte concentration. Recovery was calculated for the 
calibration curve from slope and Y-intercept obtained in linearity study 
and percentage recovery ranged from 96.0 to 102.0 presented in Table 3.
The chromatographic resolution of rizatriptan benzoate and rizatriptan 
N-oxide impurity peaks was <2.0, under all separation conditions tested 
and used to evaluate the method robustness under modified conditions 
presented in Table 4.
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Table 2: System suitability parameters and report
Parameter Results
Retention time of rizatriptan 21.7 minutes
Retention time of rizatriptan N-oxide 24.5 minutes
Resolution (USP) 7.1
*Number of theoretical plates of rizatriptan 20756
*Number of theoretical plates of rizatriptan N-oxide 494688
Tailing factor (USP) of rizatriptan 1.2
Tailing factor (USP) of rizatriptan N-oxide 1.2
*Number of theoretical plates calculated on USP tangent method
Table 3: Recovery results of R-isomer in bulk drugs
Added (ng) (n=3) Recovered (ng) % Recovery % RSD
3750 3611 96.3 2.6
7500 7223 101.5 2.5
11250 11096 99.5 2.3
RSD: Relative standard deviation
Table 4: Method robustness
S.N Parameter USP resolution between 
R-isomer and S-isomer













A new, specific, precise, and accurate gradient mode reverse phase 
liquid chromatography method was described for the separation 
of rizatriptan N-oxide in rizatriptan benzoate. The method was 
completely validated and showing satisfactory data for all the tested 
method validation parameters. The developed method can be used for 
the quantitative determination of rizatriptan N-oxide impurity in bulk 
materials.
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in rizatriptan benzoate sample during the experimentation of mobile 
phase stability. Hence, mobile phase is stable for at least 48 hrs.
